Research programme: melanocortin receptor antagonists - Taisho

Drug Profile

Research programme: melanocortin receptor antagonists - Taisho

Alternative Names: Anti-anxiety therapy - Taisho; MCL 0129

Latest Information Update: 04 Oct 2013

Price : $50

At a glance

  • Originator Taisho Pharmaceutical
  • Class Piperazines
  • Mechanism of Action Melanocortin type 4 receptor antagonists; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anxiety disorders; Major depressive disorder

Most Recent Events

  • 04 Oct 2013 Discontinued - Preclinical for Major depressive disorder in Japan (unspecified route)
  • 04 Oct 2013 Discontinued - Preclinical for Anxiety disorders in Japan (unspecified route)
  • 31 Dec 2009 No development reported - Preclinical for Major depressive disorder in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top